8-K
filed September 8, 2023, 7:59 PM ET
ticker REGN
CIK 0000872589
leadership
confidence high
sentiment neutral
materiality 0.65
Regeneron CFO Landry to retire Feb 2024; Fenimore named successor; two new directors elected
REGENERON PHARMACEUTICALS, INC.
- Director Marc Tessier-Lavigne retired Sept 1, 2023 due to potential conflicts with other roles.
- CFO Robert E. Landry to retire in Feb 2024; Christopher Fenimore (SVP, Controller) to succeed him.
- Board elected Kathryn Guarini as Class III director and David Schenkein as Class II director effective Sept 8, 2023.
- Both new directors appointed to Audit (Guarini) and Technology (Schenkein) committees.
- No disagreements cited for Landry departure; new directors hold office until 2024 annual meeting.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Marc Tessier-Lavigne retired as Director at REGENERON PHARMACEUTICALS, INC..
- Action
- retired
- Role
- Director
Exact text from the filing
On September 1, 2023, Marc Tessier-Lavigne, Ph.D. notified Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) of his decision to retire, effective as of that date, as a director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert E. Landry departed as Executive Vice President, Finance and Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..
- Action
- intends to retire
- Role
- Executive Vice President, Finance and Chief Financial Officer
Exact text from the filing
On September 8, 2023, Robert E. Landry notified the Company of his intention to retire from his position as Executive Vice President, Finance and Chief Financial Officer of the Company in February 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David P. Schenkein was elected as Class II Director at REGENERON PHARMACEUTICALS, INC..
- Action
- elected
- Role
- Class II Director
Exact text from the filing
Regeneron’s board of directors (the “ Board ”) elected Kathryn Guarini, Ph.D. as a Class III director and David P. Schenkein, M.D. as a Class II director to fill the two vacancies on the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kathryn Guarini was elected as Class III Director at REGENERON PHARMACEUTICALS, INC..
- Action
- elected
- Role
- Class III Director
Exact text from the filing
Regeneron’s board of directors (the “ Board ”) elected Kathryn Guarini, Ph.D. as a Class III director and David P. Schenkein, M.D. as a Class II director to fill the two vacancies on the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Christopher Fenimore was appointed as Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
The Company intends to appoint Christopher Fenimore, currently the Company’s Senior Vice President, Controller, to succeed Mr. Landry as Chief Financial Officer of the Company effective upon Mr. Landry’s retirement.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.